Trade LeMaitre Vascular - LMAT CFD

Add to favourite

62.45

0.84%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.31

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

LeMaitre Vascular Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	62.98
Open*	62.49
1-Year Change*	18.02%
Day's Range*	62.45 - 63.3
52 wk Range	44.27-68.67
Average Volume (10 days)	86.34K
Average Volume (3 months)	2.55M
Market Cap	1.29B
P/E Ratio	47.60
Shares Outstanding	22.26M
Revenue	185.56M
EPS	1.22
Dividend (Yield %)	0.96535
Beta	0.86
Next Earnings Date	Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	62.45	0.06	0.10%	62.39	63.38	62.36
Apr 17, 2024	62.98	-0.33	-0.52%	63.31	63.85	62.87
Apr 16, 2024	63.86	0.76	1.20%	63.10	64.40	63.10
Apr 15, 2024	64.31	-0.33	-0.51%	64.64	64.86	63.53
Apr 12, 2024	64.60	0.05	0.08%	64.55	65.26	63.67
Apr 11, 2024	65.60	-0.75	-1.13%	66.35	66.54	64.27
Apr 10, 2024	66.97	3.41	5.37%	63.56	67.07	63.56
Apr 9, 2024	66.89	3.69	5.84%	63.20	67.09	63.10
Apr 8, 2024	65.15	0.85	1.32%	64.30	65.28	63.10
Apr 5, 2024	64.19	1.09	1.73%	63.10	64.49	63.10
Apr 4, 2024	63.60	-0.23	-0.36%	63.83	64.44	63.40
Apr 3, 2024	63.76	0.03	0.05%	63.73	64.68	63.66
Apr 2, 2024	63.83	-0.99	-1.53%	64.82	64.85	63.64
Apr 1, 2024	65.84	-0.10	-0.15%	65.94	65.95	65.08
Mar 28, 2024	66.18	-0.98	-1.46%	67.16	67.54	65.61
Mar 27, 2024	66.79	0.85	1.29%	65.94	67.05	65.42
Mar 26, 2024	65.70	0.27	0.41%	65.43	66.48	65.37
Mar 25, 2024	65.33	-1.05	-1.58%	66.38	66.77	65.13
Mar 22, 2024	66.30	-1.04	-1.54%	67.34	67.38	66.12
Mar 21, 2024	67.17	0.15	0.22%	67.02	67.89	67.00

LeMaitre Vascular Events

Time (UTC)	Country	Event
Tuesday, April 30, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 LeMaitre Vascular Inc Earnings Release Q1 2024 LeMaitre Vascular Inc Earnings Release Forecast - Previous -
Friday, May 31, 2024
Time (UTC) 14:00	Country US	Event LeMaitre Vascular Inc Annual Shareholders Meeting LeMaitre Vascular Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, July 30, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 LeMaitre Vascular Inc Earnings Release Q2 2024 LeMaitre Vascular Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	161.651	154.424	129.366	117.232	105.568
Revenue	161.651	154.424	129.366	117.232	105.568
Cost of Revenue, Total	56.755	53.042	44.748	37.379	31.629
Gross Profit	104.896	101.382	84.618	79.853	73.939
Total Operating Expense	134.822	117.999	100.578	96.049	77.359
Selling/General/Admin. Expenses, Total	55.483	46.961	41.158	46.957	43.247
Research & Development	13.294	11.801	10.099	9.276	8.197
Depreciation / Amortization	6.183	6.195	5.043	2.437	1.76
Unusual Expense (Income)	3.107	0	-0.47	0	-7.474
Operating Income	26.829	36.425	28.788	21.183	28.209
Interest Income (Expense), Net Non-Operating	0.661	-2.138	-1.432	0.496	0.235
Net Income Before Taxes	27.49	34.287	27.356	21.679	28.444
Net Income After Taxes	20.636	26.907	21.22	17.934	22.543
Net Income Before Extra. Items	20.636	26.907	21.22	17.934	22.543
Net Income	20.636	26.907	21.22	17.934	22.943
Income Available to Common Excl. Extra. Items	20.636	26.907	21.22	17.934	22.543
Income Available to Common Incl. Extra. Items	20.636	26.907	21.22	17.934	22.943
Diluted Net Income	20.636	26.907	21.22	17.934	22.943
Diluted Weighted Average Shares	22.171	21.475	20.479	20.326	20.242
Diluted EPS Excluding Extraordinary Items	0.93077	1.25295	1.03618	0.88232	1.11367
Dividends per Share - Common Stock Primary Issue	0.485	0.425	0.37	0.325	0.265
Diluted Normalized EPS	1.03596	1.25295	1.01838	0.88232	0.82104
Total Extraordinary Items					0.4

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	50.115	47.075	40.954	39.028	42.108
Revenue	50.115	47.075	40.954	39.028	42.108
Cost of Revenue, Total	18.029	16.192	14.9	13.958	14.298
Gross Profit	32.086	30.883	26.054	25.07	27.81
Total Operating Expense	40.663	39.201	33.987	32.878	36.324
Selling/General/Admin. Expenses, Total	16.429	17.27	13.997	13.923	13.977
Research & Development	4.516	3.875	3.554	3.462	3.346
Depreciation / Amortization	1.509	1.559	1.536	1.535	1.596
Operating Income	9.452	7.874	6.967	6.15	5.784
Interest Income (Expense), Net Non-Operating	0.867	0.143	0.831	-0.002	-0.236
Net Income Before Taxes	10.319	8.017	7.798	6.148	5.548
Net Income After Taxes	8.098	6.04	5.627	5.456	3.515
Net Income Before Extra. Items	8.098	6.04	5.627	5.456	3.515
Net Income	8.098	6.04	5.627	5.456	3.515
Income Available to Common Excl. Extra. Items	8.098	6.04	5.627	5.456	3.515
Income Available to Common Incl. Extra. Items	8.098	6.04	5.627	5.456	3.515
Diluted Net Income	8.098	6.04	5.627	5.456	3.515
Diluted Weighted Average Shares	22.451	22.274	22.237	22.217	22.129
Diluted EPS Excluding Extraordinary Items	0.3607	0.27117	0.25305	0.24558	0.15884
Dividends per Share - Common Stock Primary Issue	0.14	0.125	0.125	0.125	0.125
Diluted Normalized EPS	0.36699	0.28148	0.25305	0.24558	0.2478
Unusual Expense (Income)	0.18	0.305	0	0	3.107

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	161.733	139.883	94.263	92.092	94.017
Cash and Short Term Investments	82.691	69.959	26.978	32.681	47.986
Cash & Equivalents	19.134	13.855	26.764	11.786	26.318
Total Receivables, Net	22.04	19.631	19.552	16.572	15.721
Accounts Receivable - Trade, Net	22.04	19.631	19.552	16.572	15.721
Total Inventory	50.271	46.104	45.115	39.527	27.388
Prepaid Expenses	6.731	4.189	2.618	3.312	2.922
Other Current Assets, Total
Total Assets	310.476	292.802	252.81	188.341	153.088
Property/Plant/Equipment, Total - Net	33.535	32.13	31.102	30.062	14.102
Property/Plant/Equipment, Total - Gross	58.659	55.061	51.187	47.834	29.446
Accumulated Depreciation, Total	-25.124	-22.931	-20.085	-17.772	-15.344
Goodwill, Net	65.945	65.945	65.945	39.951	29.868
Intangibles, Net	46.527	52.71	58.905	24.893	13.692
Other Long Term Assets, Total	2.736	2.134	2.595	1.343	1.409
Total Current Liabilities	25.329	21.813	25.145	20.851	19.758
Accounts Payable	2.903	2.34	2.394	2.604	1.732
Accrued Expenses	21.404	17.651	17.085	14.768	12.368
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	1.022	1.822	3.166	3.479	5.658
Total Liabilities	42.275	38.651	80.238	40.2	22.853
Total Long Term Debt	0	0	35.532	0	0
Deferred Income Tax	0.069	0.07	0.127	1.179	0.484
Other Liabilities, Total	16.877	16.768	19.434	18.17	2.611
Total Equity	268.201	254.151	172.572	148.141	130.235
Redeemable Preferred Stock	0	0	0		0
Common Stock	0.237	0.235	0.221	0.217	0.211
Additional Paid-In Capital	189.268	181.63	114.924	105.934	98.442
Retained Earnings (Accumulated Deficit)	97.773	88.125	70.554	57.029	45.831
Treasury Stock - Common	-13.046	-12.404	-11.602	-11.032	-10.349
Other Equity, Total	-6.031	-3.435	-1.525	-4.007	-3.9
Total Liabilities & Shareholders’ Equity	310.476	292.802	252.81	188.341	153.088
Total Common Shares Outstanding	22.0871	21.9229	20.523	20.1569	19.6087
Short Term Investments	63.557	56.104	0.214	20.895	21.668
Current Port. of LT Debt/Capital Leases		0	2.5
Long Term Debt		0	35.532

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	182.184	174.49	164.768	161.733	153.142
Cash and Short Term Investments	97.018	90.177	81.005	82.691	79.739
Cash & Equivalents	18.051	19.488	16.677	19.134	16.913
Short Term Investments	78.967	70.689	64.328	63.557	62.826
Total Receivables, Net	23.882	26.406	25.365	22.04	20.094
Accounts Receivable - Trade, Net	23.882	26.406	25.365	22.04	20.094
Total Inventory	56.187	53.831	53.779	50.271	47.711
Prepaid Expenses	5.097	4.076	4.619	6.731	4.842
Total Assets	334.012	326.467	314.866	310.476	302.048
Property/Plant/Equipment, Total - Net	37.207	37.021	34.769	33.535	31.136
Goodwill, Net	65.945	65.945	65.945	65.945	65.945
Intangibles, Net	43.199	43.999	45.508	46.527	48.063
Other Long Term Assets, Total	5.477	5.012	3.876	2.736	3.762
Total Current Liabilities	29.029	25.855	23.904	25.329	23.439
Accounts Payable	4.371	3.519	3.371	2.903	2.848
Accrued Expenses	24.091	21.264	19.297	21.404	18.82
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total	0.567	1.072	1.236	1.022	1.771
Total Liabilities	45.375	42.64	40.701	42.275	40.801
Total Long Term Debt	0	0	0	0	0
Long Term Debt
Deferred Income Tax	0.069	0.072	0.071	0.069	0.06
Other Liabilities, Total	16.277	16.713	16.726	16.877	17.302
Total Equity	288.637	283.827	274.165	268.201	261.247
Redeemable Preferred Stock	0	0	0	0	0
Common Stock	0.239	0.239	0.238	0.237	0.236
Additional Paid-In Capital	198.254	196.941	192.003	189.268	186.798
Retained Earnings (Accumulated Deficit)	110.081	105.696	100.714	97.773	94.896
Treasury Stock - Common	-13.232	-13.227	-13.218	-13.046	-12.556
Other Equity, Total	-6.705	-5.822	-5.572	-6.031	-8.127
Total Liabilities & Shareholders’ Equity	334.012	326.467	314.866	310.476	302.048
Total Common Shares Outstanding	22.2632	22.2631	22.1427	22.0871	22.0009
Other Current Assets, Total					0.756

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	20.636	26.907	21.22	17.934	22.943
Cash From Operating Activities	25.378	35.102	34.8	14.179	19.506
Cash From Operating Activities	9.433	11.07	8.395	5.416	4.324
Deferred Taxes	-0.182	0.079	-0.328	0.824	-2.152
Non-Cash Items	8.893	7.01	4.65	3.891	-3.96
Cash Taxes Paid	8.343	10.147	4.47	4.817	5.521
Changes in Working Capital	-13.402	-9.964	0.863	-13.886	-1.649
Cash From Investing Activities	-10.371	-61.076	-52.891	-24.1	-7.055
Capital Expenditures	-3.229	-4.882	-2.982	-3.761	-3.054
Other Investing Cash Flow Items, Total	-7.142	-56.194	-49.909	-20.339	-4.001
Cash From Financing Activities	-9.234	13.702	32.155	-4.622	-4.416
Financing Cash Flow Items	-1.07	-0.401	-4.551	-2.059	-1.199
Total Cash Dividends Paid	-10.988	-9.336	-7.695	-6.736	-5.445
Issuance (Retirement) of Stock, Net	2.824	62.439	5.401	4.173	2.228
Foreign Exchange Effects	-0.494	-0.637	0.914	0.011	-0.813
Net Change in Cash	5.279	-12.909	14.978	-14.532	7.222
Issuance (Retirement) of Debt, Net	0	-39	39

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	6.04	20.636	15.009	9.553	6.038
Cash From Operating Activities	2.279	25.378	21.301	13.959	4.711
Cash From Operating Activities	2.351	9.433	7.145	4.817	2.373
Non-Cash Items	2.001	8.893	7.093	5.191	1.265
Cash Taxes Paid	-0.271	8.343	6.822	3.991	0.731
Changes in Working Capital	-8.113	-13.402	-7.946	-5.602	-4.965
Cash From Investing Activities	-2.964	-10.371	-9.969	-1.509	-0.536
Capital Expenditures	-2.13	-3.229	-1.969	-1.509	-0.536
Other Investing Cash Flow Items, Total	-0.834	-7.142	-8		0
Cash From Financing Activities	-1.825	-9.234	-7.112	-4.965	-2.38
Total Cash Dividends Paid	-3.099	-10.988	-8.238	-5.488	-2.743
Issuance (Retirement) of Stock, Net	1.274	2.824	1.527	0.523	0.363
Issuance (Retirement) of Debt, Net		0	0	0	0
Foreign Exchange Effects	0.053	-0.494	-1.162	-0.552	-0.09
Net Change in Cash	-2.457	5.279	3.058	6.933	1.705
Financing Cash Flow Items		-1.07	-0.401
Deferred Taxes		-0.182

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

LeMaitre Vascular Company profile

About LeMaitre Vascular Inc

LeMaitre Vascular, Inc. is a medical device company. The Company provides medical devices and human tissue cryopreservation services used in the treatment of peripheral vascular disease, end-stage renal disease and cardiovascular disease. It develops, manufactures and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons and neurosurgeons. Its portfolio of devices consists of products that are used in arteries and veins outside of the heart, which includes the LeMaitre valvulotome, the XenoSure biologic patch, the Artegraft collagen vascular graft, the Pruitt F3 carotid shunt, VascuTape radiopaque tape and Syntel embolectomy catheters. Its product line includes Valvulotomes, Surgical Glue, Remote Endarterectomy Devices, Radiopaque Tape, Powered Phlebectomy, ePTFE Vascular Grafts, Polyester Vascular Grafts, Ovine Vascular Grafts, Closure Systems, Carotid Shunts, Allografts, Angioscopes and many others.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, LeMaitre Vascular Inc revenues increased 19% to $154.4M. Net income increased 27% to $26.9M. Revenues reflect United States segment increase of 25% to $93.9M, Other countries segment increase of 14% to $47.6M. Net income benefited from Foreign currency loss decrease of 65% to $116K (expense). Dividend per share increased from $0.37 to $0.43.

Equity composition

Common Stock $.01 Par, 03/11, 100M auth., 16,144,485 issd., less 639,155 shs. in Treas. @ $3.8M. Insiders control 36.71%. IPO: 10/06,5.5M shs. @ $7 per share by Goldman, Sachs & Co., CIBC Worlds Markets, Cowen & Co. and Thomas Weisel Partners LLC. Pref. Stock $.01 Par, 5M auth.,none issued.

Industry:

Advanced Medical Equipment & Technology (NEC)

63 2nd Ave
BURLINGTON
MASSACHUSETTS 01803
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024